FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Approved Immunology Drugs in Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Human Immune Globulin

            Therapeutic Area: Immunology

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Morgan Stanley

            Deal Size: $94.6 million Upfront Cash: Undisclosed

            Deal Type: Public Offering February 24, 2020

            Details:

            ADMA intends to use the net proceeds from this offering (i) for the procurement of raw materials for the manufacturing of BIVIGAM and ASCENIV.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Human Immune Globulin

            Therapeutic Area: Immunology

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Morgan Stanley

            Deal Size: $82.3 million Upfront Cash: Undisclosed

            Deal Type: Public Offering February 06, 2020

            Details:

            ADMA intends to use the net proceeds to procure raw materials for the production of BIVIGAM and ASCENIV, to support their marketing and other corporate purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Peanut (Arachis hypogaea) Allergen-dnfp

            Therapeutic Area: Immunology

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Nestle Health Science

            Deal Size: $473.0 million Upfront Cash: Undisclosed

            Deal Type: Investment February 05, 2020

            Details:

            Nestle Health Science's investment in Aimmune is intended to help assure PALFORZIA’s longer-term commercial success and allow Aimmune to continue making progress in food allergy treatments.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Adalimumab

            Therapeutic Area: Immunology

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Samsung Bioepis

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership January 16, 2020

            Details:

            The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab), and SB8 (bevacizumab).